Literature DB >> 28647891

Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.

Davide Imberti1, Daniela Mastroiacovo2.   

Abstract

In the Hokusai-VTE trial, 733 patients were treated with the reduced dose edoxaban regimen, which maintained efficacy and safety compared with the 60 mg dose, and was safer than warfarin. The prophylactic doses of apixaban and rivaroxaban reduced the risk of recurrent venous thromboembolism (VTE) in the extended treatment trials. Dabigatran 110 mg was approved by the European Medicine Agency for VTE treatment. Further data from registries and real-world studies will help to clarify whether patients, with other specific characteristics, can benefit from the reduced dose of direct oral anticoagulants.

Entities:  

Keywords:  Direct oral anticoagulants (DOACs); Lower dose; Venous thromboembolism

Mesh：

Substances：

Year:  2017        PMID： 28647891     DOI： 10.1007/s11739-017-1688-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


  18 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Italian intersociety consensus on DOAC use in internal medicine.

Authors:  Domenico Prisco; Walter Ageno; Cecilia Becattini; Armando D'Angelo; Giovanni Davì; Raimondo De Cristofaro; Francesco Dentali; Giovanni Di Minno; Anna Falanga; Gualberto Gussoni; Luca Masotti; Gualtiero Palareti; Pasquale Pignatelli; Roberto M Santi; Francesca Santilli; Mauro Silingardi; Antonella Tufano; Francesco Violi
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

3.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Authors:  Jeffrey I Weitz; Anthonie W A Lensing; Martin H Prins; Rupert Bauersachs; Jan Beyer-Westendorf; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Maria C S Freitas; Gerlind Holberg; Ajay K Kakkar; Lloyd Haskell; Bonno van Bellen; Akos F Pap; Scott D Berkowitz; Peter Verhamme; Philip S Wells; Paolo Prandoni
Journal:  N Engl J Med       Date:  2017-03-18       Impact factor: 91.245

Review 4.  Use of novel oral anticoagulant agents in venous thromboembolism.

Authors:  Shivanshu Madan; Shenil Shah; Patrick Dale; Sasan Partovi; Sahil A Parikh
Journal:  Cardiovasc Diagn Ther       Date:  2016-12

5.  Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.

Authors:  Javier Trujillo-Santos; Pierpaolo Di Micco; Francesco Dentali; James Douketis; José Antonio Díaz-Peromingo; Manuel Jesús Núñez; Inmaculada Cañas; Daniela Mastroiacovo; Marta Saraiva de Sousa; Manuel Monreal
Journal:  Thromb Haemost       Date:  2016-10-27       Impact factor: 5.249

6.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

7.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

Authors:  Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

Review 8.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

Authors:  Nick van Es; Michiel Coppens; Sam Schulman; Saskia Middeldorp; Harry R Büller
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

9.  Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.

Authors:  Megan E Barra; John Fanikos; Jean M Connors; Katelyn W Sylvester; Gregory Piazza; Samuel Z Goldhaber
Journal:  Am J Med       Date:  2016-06-21       Impact factor: 4.965

10.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245
View more
  1 in total

1.  Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.

Authors:  Davide Imberti; Cecilia Becattini; Enrico Bernardi; Giuseppe Camporese; Claudio Cuccia; Francesco Dentali; Damiano Paretti
Journal:  Intern Emerg Med       Date:  2018-03-08       Impact factor: 3.397
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.